Overview

Short-course Methenamine Hippurate for Prevention of Post-operative UTI

Status:
Completed
Trial end date:
2020-09-30
Target enrollment:
0
Participant gender:
Female
Summary
The investigators will determine the efficacy of an innovative short regimen of methenamine hippurate on prevention of post-operative UTI in patients requiring short-term catheterization after pelvic reconstructive surgery through a single-blind, randomized controlled trial. Primary outcome will be the rate of symptomatic UTI within 3 weeks of catheter removal. The investigators will study cost-effectiveness, antibiotic resistance profiles, and adverse drug effects. Findings may reduce antibiotic use and nosocomial UTIs.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Pennsylvania
Treatments:
Ciprofloxacin
Methenamine
Methenamine hippurate
Methenamine mandelate
Criteria
Inclusion Criteria:

- female;

- patients who are able to read and write English;

- 18 years of age or older;

- underwent surgery for pelvic organ prolapse, urinary incontinence, or both;

- require post-operative short-term transurethral catheterization for greater than 24
hours.

Exclusion Criteria:

- patients undergoing surgical intervention for sacral neuromodulation, or mesh
excision;

- patients requiring long-term catheterization secondary to injury to the urinary tract;

- patients who pass their post-operative trial void and thus, do not require additional
catheterization;

- patients requiring catheterization for less than 24 hours;

- pregnant patients;

- patients who are breast-feeding;

- allergy to methenamine hippurate or fluroquinolones (either ciprofloxacin or
levofloxacin);

- impaired renal or hepatic function;

- pre-operative urinary retention;

- patients who are currently using sulfonamides;

- patients who have severe dehydration;

- patients using tizanidine;

- patients sensitive to quinolones class;

- patients using theophylline; patients with myasthenia gravis;

- patients with prolongation of QT interval.